Therapeutic Vaccines Track

 

 

With so much activity around auto-immune diseases from allergy to chronic infectious diseases to cancer vaccines and immunotherapy, can you afford to miss out?

It is the place where the global market will come together to share the latest in early-stage scientific advancements, present clinical trial data, discuss new formulations of therapeutic vaccines and assess the future of combination treatments.

Make sure that people are aware of the work you are doing to put yourself at the forefront of the industry.

 

 

Who Sponsors?

 

 

This is a prime opportunity for specialists in oncology from:

• Platform Technology Providers
• Big Pharma
• Biotechs

Who Attends

 

 

• Pharma
• Biotechs
• National and International Government
• Non-Profit Organizations
• Academics And Research Institutions

Job Titles

 

 

• CEO / CSO COO
• CMO / Head of Scientific Affairs
• Head of Immunotherapy
• Head of Allergy
• Head of Oncology
• Head of Immuno-Oncology
• Head of R&D

 
 

 

2018 AGENDA

 

Immuno-Oncology Profiling, Tuesday 30 October 2018

Opening Plenary Session

Dr Elizabeth Klemm
09:40

Short morning break followed by session tracks

Immuno-Oncology Profiling
10:00

Chair’s opening remarks

Immuno-Oncology Profiling

Promising Immunotherapy Approaches

Dr Carl Barrett
Immuno-Oncology Profiling
10:05

Improving the accuracy of tools for personalized medicine- ctDNA

Dr Philip Beer
Immuno-Oncology Profiling
10:35

The use of genomics in predicting response to immunotherapy

11:05

Morning Networking Break

Dr Philippe Duchateau
Immuno-Oncology Profiling
12:05

How do we overcome CAR T immunotherapy limitations to enable the treatment of more patients?

Dr David Gilham
Immuno-Oncology Profiling
12:35

Combining Innate and Adaptive Immunity: NK Receptors for CAR T Cell Therapy

Dr Peter Timmerman
Immuno-Oncology Profiling
13:05

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

Immuno-Oncology Profiling
13:20

A new immunomodulatory strategy of releasing immunosuppression in the tumour microenvironment

13:35

Networking Lunch & Poster Session

Dr Adel Samson
Immuno-Oncology Profiling
15:05

Priming tumours for immune checkpoint blockade using oncolytic viruses

Dr Douglas Mcneel
Immuno-Oncology Profiling
15:35

Synergy of DNA Vaccines with checkpoint inhibitors and Standard of Care Agents for Prostate Cancer

  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer with anti-PD-1
  • DNA vaccines to augment androgen deprivation therapy
Professor Lana Kandalaft
Immuno-Oncology Profiling
16:05

Hope for late-stage ovarian cancer: Development of a personalized dendritic cell vaccine

  • Improving dendritic cell platforms
  • Initiating large scale trials and combination therapies
Dr Mai-Britt Zocca
Immuno-Oncology Profiling
16:35

Targeting IDO positive cells with IO102, an immune modulating vaccine

Dr Cristina Peixoto
Immuno-Oncology Profiling
17:05

Improving cancer vaccine manufacturing to GMP compatible bioprocesses

Chair closing remarks of day one followed by Drinks Reception

last published: 17/Aug/18 15:45

Immuno-Oncology Profiling, Wednesday 31 October 2018

Immuno-Oncology Profiling
09:00

Chair’s opening remarks

Immuno-Oncology Profiling

Combination Strategies

Dr Maria Karasarides
Immuno-Oncology Profiling
09:10

How do we maximize the therapeutic potential of Immuno-oncology through novel combinations?

Dr Jun Wang
Immuno-Oncology Profiling
09:40

Rational design of immunotherapy combinations for GI/solid tumour treatment

Morena D'Alise
Immuno-Oncology Profiling
10:10

Primate derived adenovectors synergize with immunomodulators for the treatment of established tumors

10:40

Morning Networking Break

Dr Alfredo Zurlo
Immuno-Oncology Profiling
11:20

Antibody based combination immunotherapy

Immuno-Oncology Profiling
11:50

Use of agonistic targets such as CD137 and OX40 to activate the antitumor immune T cell response

Dr Mark Throsby
Immuno-Oncology Profiling
12:20

Unbiased functional screening of large bispecific antibody panels to unlock novel biology

12:50

Afternoon Networking Lunch

AFTERNOON PLENARY TALKS

Dr Giovanna Zanoni
14:00

Status of vaccine confidence around the world

  • Social and political factors that can affect uptake of vaccines
  • How can we better educate the public the benefits of immunisation?
  • How can public health institutions, government and vaccine developers help with building a coherent story
  • AEFI surveillance and risk communication
  • Are we overlooking the power of social media?
Dr Helen Bright
14:50

Flumist vaccine effectiveness – It’s return and the real story

  • Questions over the effectiveness of the live attenuated vaccine
  • Why it lost its recommendation
  • The journey, investigation and trial data to rectify this
Dr Rino Rappuoli

Chair’s closing remarks and close of congress

last published: 17/Aug/18 15:45

 
 

Sign Up for Event Updates